<DOC>
	<DOCNO>NCT00004736</DOCNO>
	<brief_summary>The purpose study see type anti-HIV therapy call HAART effective lowering level HIV boost immune system HIV-infected patient tuberculosis ( TB ) . HIV-infected patient TB high level HIV low CD4 cell count ( cell body fight infection ) HIV-infected patient without TB . HAART effective reduce HIV level increase CD4 cell patient without TB . However , effect HIV-infected patient TB unknown .</brief_summary>
	<brief_title>Effectiveness Anti-HIV Therapy ( HAART ) HIV-Infected Patients With Tuberculosis</brief_title>
	<detailed_description>Previous study focus characterize viral immune dynamic initiation HAART patient without opportunistic infection . The development TB HIV-infected individual associate elevation HIV RNA level , decrease CD4 cell count , increase activate ( CD38 ) lymphocytes proinflammatory cytokine ( IL-1 , TNF-alpha , IL-6 ) . Response HAART may differ individual active opportunistic infection TB . HIV-infected patient active TB follow anti-TB regimen include rifabutin observe maximum 24 week initiate HAART . Plasma sample 24-hour post-rifabutin dosing collect entry Weeks 4 , 8 , 12 , Weeks 2 , 3 , 4 , 12 , 24 HAART initiation . Analyses sample use explore relationship cytokine rifabutin metabolism effect nelfinavir rifabutin pharmacokinetics . The HAART regimen nelfinavir plus lamivudine ( 3TC ) plus either zidovudine ( ZDV ) stavudine ( d4T ) . After initiation HAART , patient undergo intensive monitoring viral immune dynamic 2 month . The patient continue follow 1 year time start HAART . Neither HAART drug regimen anti-TB medication provide study must obtain prescription . If patient intolerant HAART regimen exhibit virologic rebound , primary provider alter modify regimen . As part substudy A5065s , patient experience sign symptom paradoxical reaction ( i.e. , new persistent fever develop initiate HAART last 1 week without identifiable source ; mark worsen emergence intrathoracic lymphadenopathy , pulmonary infiltrates ; worsen emergence cervical adenopathy serial physical examination ; worsen tuberculous lesion ) additional clinical evaluation ( include chest x-ray , target clinical assessment , concomitant medication , sign symptom ) weekly 4 week , every month thereafter symptoms resolve .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have HIV RNA level 20,000 copies/ml within 30 day study entry . Are least 18 year old . Agree use effective method birth control study . Agree treat rifabutin least 2 week start HAART ( apply patient infected TB ) . Plan start HAART within 6 month start TB therapy ( applies patient infected TB ) . Can take 3TC , nelfinavir , either ZDV d4T . Are available followup least 1 year . Exclusion Criteria Patients eligible study : Have take combination antiHIV drug great 3 month . Have start HAART since infect TB ( apply patient infected TB ) . Are resistant one medication use treat TB ( apply patient infected TB ) . Have 16 week TB therapy ( applies patient infected TB ) . Are take rifampin treat TB switch rifabutin least 2 week start HAART ( apply patient infected TB ) . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Rifabutin</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Antitubercular Agents</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>